@Dungiven, I am floored by your notes. No offence taken whatsoever. Thanks for taking the trouble to record it. My main concern in inviting last year was product failure in SUBRE and Aspiral, leading to permanent capital loss. To say we are beyond that is blind exuberance. But as we get progressive traction, FLC is getting more derisked. My grateful thanks again.
Add to My Watchlist
What is My Watchlist?
